Kiadis shares yo-yo on cell therapy trial for COVID-19

Shares in Netherlands biotech Kiadis rose sharply on the news that it would start developing a natural killer (NK) cell therapy for COVID-19, but later lost most of the gains o

Kiadis sheds half its staff as lead cell therapy bombs